AG˹ٷ

STOCK TITAN

[8-K] Amneal Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

NCSM’s Q2-25 10-Q shows a clear YoY turnaround. Revenue rose 23% to $36.5 mm, driven by a 46% jump in product sales that offset an 19% decline in service revenue. Consolidated gross profit improved $2.5 mm and the operating loss narrowed to $2.0 mm from $4.2 mm. A $1.0 mm deferred-tax benefit plus FX gains lifted net income attributable to NCS to $0.9 mm ($0.34 diluted EPS) versus a $3.1 mm loss (-$1.21) last year.

For the six months, revenue climbed 18% to $86.5 mm and net income swung to $5.0 mm ($1.84 diluted EPS). Canada contributed 49% of Q2 sales, the U.S. 37%, and other markets 14%.

Balance sheet. Cash remained healthy at $25.4 mm; NCS drew no amounts on its $35 mm ABL facility. Total debt consists solely of $7.7 mm of finance leases. Equity increased to $124.0 mm.

Cash flow. H1 operating cash inflow fell to $1.9 mm from $4.1 mm on higher working-capital needs; capex was modest at $0.7 mm.

Strategic update. On 31-Jul-25 NCS closed the $5.9 mm cash acquisition of Reservoir Metrics to expand tracer diagnostics, with an earn-out of up to $1.3 mm.

Risks & Outlook. Management cites stable Canadian activity, softer U.S. completions, potential international growth, and cost headwinds from steel/chemical tariffs. Ongoing Canadian patent appeals and U.S. litigation could affect future results but no gain/loss has been booked.

Il 10-Q del secondo trimestre 2025 di NCSM mostra un chiaro miglioramento anno su anno. I ricavi sono aumentati del 23% raggiungendo 36,5 milioni di dollari, grazie a un incremento del 46% delle vendite di prodotti che ha compensato un calo del 19% dei ricavi dai servizi. Il margine lordo consolidato è cresciuto di 2,5 milioni di dollari e la perdita operativa si è ridotta a 2,0 milioni di dollari dai 4,2 milioni precedenti. Un beneficio fiscale differito di 1,0 milione di dollari e guadagni da cambio hanno portato l'utile netto attribuibile a NCS a 0,9 milioni di dollari (EPS diluito di 0,34$) rispetto a una perdita di 3,1 milioni (-1,21$) dell'anno scorso.

Nei primi sei mesi, i ricavi sono aumentati del 18% a 86,5 milioni di dollari e l'utile netto è passato a 5,0 milioni di dollari (EPS diluito di 1,84$). Il Canada ha contribuito per il 49% alle vendite del secondo trimestre, gli Stati Uniti per il 37% e altri mercati per il 14%.

Bilancio. La liquidità è rimasta solida a 25,4 milioni di dollari; NCS non ha utilizzato la linea di credito ABL da 35 milioni di dollari. Il debito totale è composto esclusivamente da 7,7 milioni di dollari di leasing finanziari. Il patrimonio netto è salito a 124,0 milioni di dollari.

Flusso di cassa. Il flusso di cassa operativo nel primo semestre è sceso a 1,9 milioni di dollari dai 4,1 milioni precedenti a causa di maggiori esigenze di capitale circolante; gli investimenti in capitale sono stati contenuti a 0,7 milioni di dollari.

Aggiornamento strategico. Il 31 luglio 2025 NCS ha completato l’acquisizione in contanti da 5,9 milioni di dollari di Reservoir Metrics per espandere la diagnostica dei traccianti, con un earn-out fino a 1,3 milioni di dollari.

Rischi e prospettive. La direzione segnala un’attività stabile in Canada, un rallentamento nelle completions negli USA, potenziali opportunità di crescita internazionale e pressioni sui costi dovute a tariffe su acciaio e prodotti chimici. Le controversie brevettuali in Canada e le cause legali negli USA potrebbero influenzare i risultati futuri, ma non sono state registrate perdite o guadagni al momento.

El informe 10-Q del segundo trimestre de 2025 de NCSM muestra una clara recuperación interanual. Los ingresos aumentaron un 23% hasta 36,5 millones de dólares, impulsados por un salto del 46% en las ventas de productos que compensó una caída del 19% en los ingresos por servicios. El beneficio bruto consolidado mejoró en 2,5 millones de dólares y la pérdida operativa se redujo a 2,0 millones desde 4,2 millones. Un beneficio fiscal diferido de 1,0 millón y ganancias por tipo de cambio elevaron el ingreso neto atribuible a NCS a 0,9 millones de dólares (EPS diluido de 0,34$) frente a una pérdida de 3,1 millones (-1,21$) del año anterior.

En los primeros seis meses, los ingresos subieron un 18% hasta 86,5 millones y el ingreso neto pasó a 5,0 millones de dólares (EPS diluido de 1,84$). Canadá aportó el 49% de las ventas del segundo trimestre, EE.UU. el 37% y otros mercados el 14%.

Balance general. El efectivo se mantuvo saludable en 25,4 millones; NCS no utilizó su línea de crédito ABL de 35 millones. La deuda total consiste únicamente en 7,7 millones en arrendamientos financieros. El patrimonio neto aumentó a 124,0 millones.

Flujo de caja. El flujo de caja operativo en el primer semestre cayó a 1,9 millones desde 4,1 millones debido a mayores necesidades de capital de trabajo; la inversión en capital fue modesta, 0,7 millones.

Actualización estratégica. El 31 de julio de 2025, NCS cerró la adquisición en efectivo de Reservoir Metrics por 5,9 millones para ampliar el diagnóstico de trazadores, con un earn-out de hasta 1,3 millones.

Riesgos y perspectivas. La dirección menciona actividad estable en Canadá, una menor actividad en completaciones en EE.UU., potencial crecimiento internacional y presiones de costos por aranceles en acero y productos químicos. Las apelaciones de patentes en Canadá y litigios en EE.UU. podrían afectar resultados futuros, pero no se ha registrado ninguna ganancia o pérdida hasta ahora.

NCSM� 2025� 2분기 10-Q 보고서는 명확� 전년 대� 반전세를 보여줍니�. 매출은 23% 증가� 3,650� 달러� 기록했으�, 제품 판매가 46% 급증� 서비� 매출 19% 감소� 상쇄했습니다. 연결 총이익은 250� 달러 개선되었�, 영업 손실은 420� 달러에서 200� 달러� 축소되었습니�. 100� 달러� 이연 세금 혜택� 환율 이익으로 NCS 귀� 순이익은 90� 달러(희석 주당순이� 0.34달러)�, 작년 310� 달러 손실(-1.21달러)에서 흑자� 전환되었습니�.

상반� 매출은 18% 증가� 8,650� 달러, 순이익은 500� 달러(희석 주당순이� 1.84달러)� 전환되었습니�. 2분기 매출� 49%� 캐나�, 37%� 미국, 14%� 기타 시장에서 발생했습니다.

재무�. 현금은 2,540� 달러� 건전하며, NCS� 3,500� 달러 ABL 시설� � 푼도 사용하지 않았습니�. � 부채는 770� 달러� 금융리스� 포함합니�. 자본은 1� 2,400� 달러� 증가했습니다.

현금 흐름. 상반� 영업 현금 유입은 운전자본 수요 증가� 410� 달러에서 190� 달러� 감소했으�, 자본적지출은 70� 달러� 적당했습니다.

전략 업데이트. 2025� 7� 31�, NCS� 추적 진단 분야 확장� 위해 Reservoir Metrics� 590� 달러 현금으로 인수했으�, 최대 130� 달러� 추가 지� 조건(언아�)� 있습니다.

위험 � 전망. 경영진은 캐나� 활동은 안정적이�, 미국 완성 작업은 다소 둔화되고, 국제 성장 가능성 � 철강/화학 관세로 인한 비용 압박� 언급했습니다. 캐나� 특허 항소 � 미국 소송� 향후 실적� 영향� 미칠 � 있으�, 현재까지 손익은 반영되지 않았습니�.

Le rapport 10-Q du deuxième trimestre 2025 de NCSM montre un net retournement annuel. Le chiffre d'affaires a augmenté de 23 % pour atteindre 36,5 millions de dollars, porté par une hausse de 46 % des ventes de produits qui a compensé une baisse de 19 % des revenus de services. Le bénéfice brut consolidé s'est amélioré de 2,5 millions de dollars et la perte d'exploitation s'est réduite à 2,0 millions de dollars contre 4,2 millions précédemment. Un avantage fiscal différé de 1,0 million de dollars ainsi que des gains de change ont porté le résultat net attribuable à NCS à 0,9 million de dollars (BPA dilué de 0,34 $) contre une perte de 3,1 millions (-1,21 $) l'année dernière.

Sur six mois, le chiffre d'affaires a progressé de 18 % pour atteindre 86,5 millions de dollars et le résultat net est passé à 5,0 millions de dollars (BPA dilué de 1,84 $). Le Canada a contribué à 49 % des ventes du deuxième trimestre, les États-Unis à 37 % et les autres marchés à 14 %.

Bilan. La trésorerie est restée solide à 25,4 millions de dollars ; NCS n'a tiré aucun montant sur sa facilité ABL de 35 millions. La dette totale se compose uniquement de 7,7 millions en contrats de location-financement. Les capitaux propres ont augmenté à 124,0 millions.

Flux de trésorerie. Les flux de trésorerie d'exploitation du premier semestre ont chuté à 1,9 million contre 4,1 millions en raison d'un besoin accru en fonds de roulement ; les dépenses d'investissement ont été modestes à 0,7 million.

Mise à jour stratégique. Le 31 juillet 2025, NCS a finalisé l'acquisition en numéraire de Reservoir Metrics pour 5,9 millions, afin d'élargir le diagnostic des traceurs, avec un complément de prix pouvant atteindre 1,3 million.

Risques et perspectives. La direction évoque une activité stable au Canada, un ralentissement des opérations de complétion aux États-Unis, une croissance internationale potentielle et des pressions sur les coûts dues aux droits sur l'acier et les produits chimiques. Les appels en matière de brevets au Canada et les litiges aux États-Unis pourraient affecter les résultats futurs, mais aucun gain ou perte n'a été comptabilisé à ce jour.

Der 10-Q-Bericht von NCSM für das zweite Quartal 2025 zeigt eine klare positive Jahresvergleichsentwicklung. Der Umsatz stieg um 23 % auf 36,5 Mio. USD, angetrieben durch einen 46%igen Anstieg der Produktverkäufe, der einen 19%igen Rückgang der Serviceerlöse ausglich. Der konsolidierte Bruttogewinn verbesserte sich um 2,5 Mio. USD, und der operative Verlust verringerte sich von 4,2 Mio. USD auf 2,0 Mio. USD. Ein latenter Steuergewinn von 1,0 Mio. USD sowie Wechselkursgewinne führten dazu, dass der auf NCS entfallende Nettogewinn 0,9 Mio. USD betrug (verwässertes EPS von 0,34 USD) gegenüber einem Verlust von 3,1 Mio. USD (-1,21 USD) im Vorjahr.

Für die ersten sechs Monate stiegen die Umsätze um 18 % auf 86,5 Mio. USD, und der Nettogewinn drehte auf 5,0 Mio. USD (verwässertes EPS von 1,84 USD). Kanada trug 49 % zum Umsatz im zweiten Quartal bei, die USA 37 % und andere Märkte 14 %.

Bilanz. Die Zahlungsmittel blieben mit 25,4 Mio. USD gesund; NCS zog keine Beträge aus seiner 35 Mio. USD ABL-Kreditlinie ab. Die Gesamtschulden bestehen ausschließlich aus 7,7 Mio. USD Finanzierungsleasing. Das Eigenkapital stieg auf 124,0 Mio. USD.

Cashflow. Der operative Cashflow im ersten Halbjahr sank auf 1,9 Mio. USD von 4,1 Mio. USD aufgrund höherer Working-Capital-Bedürfnisse; die Investitionen in Sachanlagen waren mit 0,7 Mio. USD moderat.

Strategisches Update. Am 31. Juli 2025 schloss NCS die Barübernahme von Reservoir Metrics für 5,9 Mio. USD ab, um die Tracer-Diagnostik zu erweitern, mit einem Earn-out von bis zu 1,3 Mio. USD.

Risiken & Ausblick. Das Management nennt stabile Aktivitäten in Kanada, eine schwächere Fertigstellungstätigkeit in den USA, potenzielles internationales Wachstum und Kostendruck durch Stahl-/Chemiezölle. Laufende Patentberufungen in Kanada und Rechtsstreitigkeiten in den USA könnten zukünftige Ergebnisse beeinflussen, es wurden jedoch bisher keine Gewinne oder Verluste verbucht.

Positive
  • Revenue up 23% YoY in Q2-25, with product sales +46%.
  • Return to profitability: $0.9 mm net income vs. $3.1 mm loss prior year; diluted EPS $0.34.
  • Strong liquidity: $25.4 mm cash, no ABL borrowings, net leverage �0.
  • Equity grew to $124 mm; book value strengthened.
  • Accretive bolt-on acquisition of Reservoir Metrics for $5.9 mm expands tracer diagnostics.
Negative
  • Service revenue fell 19% YoY, signaling softer utilization.
  • Operating cash flow down to $1.9 mm from $4.1 mm due to working-capital build.
  • Ongoing litigation in Canada (Kobold) and U.S. appeals create financial uncertainty.
  • Tariff exposure on steel and Chinese chemicals could squeeze margins.
  • Seasonal and macro headwinds expected to reduce U.S. activity in H2-25.

Insights

TL;DR � Swing to profitability, solid liquidity, modest acquisition; overall positive.

Revenue growth was volume-led, with Canadian product sales the standout. The mix shift lifted gross profit despite service softness. Net income turned positive for both the quarter and YTD, aided by a $1.4 mm valuation-allowance release. Cash of $25 mm covers short-term needs and there is no ABL draw, leaving ample headroom. The small $5.9 mm Reservoir Metrics deal is easily financed and deepens the high-margin tracer line. Net leverage is effectively zero, giving flexibility should market conditions worsen. Guidance commentary suggests flat-to-down U.S. activity but stable Canada, implying H2 revenue may seasonally improve yet trail H1 levels. Overall, the filing signals improving fundamentals and prudent capital deployment.

TL;DR � Litigation and tariff exposure temper otherwise improving fundamentals.

While metrics improved, several contingencies persist. Canadian patent disputes with Kobold could ultimately impose damages or product constraints; timing remains uncertain. U.S. litigation wins against Nine and TCO are under appeal, so gains are non-cash for now. Tariff volatility—steel, aluminum and China-sourced chemicals—could pressure margins given limited pricing power in competitive markets. Operating cash flow weakened on higher inventories and receivables, a trend to monitor if activity slows. Nevertheless, zero revolver borrowings and modest capex reduce liquidity risk.

Il 10-Q del secondo trimestre 2025 di NCSM mostra un chiaro miglioramento anno su anno. I ricavi sono aumentati del 23% raggiungendo 36,5 milioni di dollari, grazie a un incremento del 46% delle vendite di prodotti che ha compensato un calo del 19% dei ricavi dai servizi. Il margine lordo consolidato è cresciuto di 2,5 milioni di dollari e la perdita operativa si è ridotta a 2,0 milioni di dollari dai 4,2 milioni precedenti. Un beneficio fiscale differito di 1,0 milione di dollari e guadagni da cambio hanno portato l'utile netto attribuibile a NCS a 0,9 milioni di dollari (EPS diluito di 0,34$) rispetto a una perdita di 3,1 milioni (-1,21$) dell'anno scorso.

Nei primi sei mesi, i ricavi sono aumentati del 18% a 86,5 milioni di dollari e l'utile netto è passato a 5,0 milioni di dollari (EPS diluito di 1,84$). Il Canada ha contribuito per il 49% alle vendite del secondo trimestre, gli Stati Uniti per il 37% e altri mercati per il 14%.

Bilancio. La liquidità è rimasta solida a 25,4 milioni di dollari; NCS non ha utilizzato la linea di credito ABL da 35 milioni di dollari. Il debito totale è composto esclusivamente da 7,7 milioni di dollari di leasing finanziari. Il patrimonio netto è salito a 124,0 milioni di dollari.

Flusso di cassa. Il flusso di cassa operativo nel primo semestre è sceso a 1,9 milioni di dollari dai 4,1 milioni precedenti a causa di maggiori esigenze di capitale circolante; gli investimenti in capitale sono stati contenuti a 0,7 milioni di dollari.

Aggiornamento strategico. Il 31 luglio 2025 NCS ha completato l’acquisizione in contanti da 5,9 milioni di dollari di Reservoir Metrics per espandere la diagnostica dei traccianti, con un earn-out fino a 1,3 milioni di dollari.

Rischi e prospettive. La direzione segnala un’attività stabile in Canada, un rallentamento nelle completions negli USA, potenziali opportunità di crescita internazionale e pressioni sui costi dovute a tariffe su acciaio e prodotti chimici. Le controversie brevettuali in Canada e le cause legali negli USA potrebbero influenzare i risultati futuri, ma non sono state registrate perdite o guadagni al momento.

El informe 10-Q del segundo trimestre de 2025 de NCSM muestra una clara recuperación interanual. Los ingresos aumentaron un 23% hasta 36,5 millones de dólares, impulsados por un salto del 46% en las ventas de productos que compensó una caída del 19% en los ingresos por servicios. El beneficio bruto consolidado mejoró en 2,5 millones de dólares y la pérdida operativa se redujo a 2,0 millones desde 4,2 millones. Un beneficio fiscal diferido de 1,0 millón y ganancias por tipo de cambio elevaron el ingreso neto atribuible a NCS a 0,9 millones de dólares (EPS diluido de 0,34$) frente a una pérdida de 3,1 millones (-1,21$) del año anterior.

En los primeros seis meses, los ingresos subieron un 18% hasta 86,5 millones y el ingreso neto pasó a 5,0 millones de dólares (EPS diluido de 1,84$). Canadá aportó el 49% de las ventas del segundo trimestre, EE.UU. el 37% y otros mercados el 14%.

Balance general. El efectivo se mantuvo saludable en 25,4 millones; NCS no utilizó su línea de crédito ABL de 35 millones. La deuda total consiste únicamente en 7,7 millones en arrendamientos financieros. El patrimonio neto aumentó a 124,0 millones.

Flujo de caja. El flujo de caja operativo en el primer semestre cayó a 1,9 millones desde 4,1 millones debido a mayores necesidades de capital de trabajo; la inversión en capital fue modesta, 0,7 millones.

Actualización estratégica. El 31 de julio de 2025, NCS cerró la adquisición en efectivo de Reservoir Metrics por 5,9 millones para ampliar el diagnóstico de trazadores, con un earn-out de hasta 1,3 millones.

Riesgos y perspectivas. La dirección menciona actividad estable en Canadá, una menor actividad en completaciones en EE.UU., potencial crecimiento internacional y presiones de costos por aranceles en acero y productos químicos. Las apelaciones de patentes en Canadá y litigios en EE.UU. podrían afectar resultados futuros, pero no se ha registrado ninguna ganancia o pérdida hasta ahora.

NCSM� 2025� 2분기 10-Q 보고서는 명확� 전년 대� 반전세를 보여줍니�. 매출은 23% 증가� 3,650� 달러� 기록했으�, 제품 판매가 46% 급증� 서비� 매출 19% 감소� 상쇄했습니다. 연결 총이익은 250� 달러 개선되었�, 영업 손실은 420� 달러에서 200� 달러� 축소되었습니�. 100� 달러� 이연 세금 혜택� 환율 이익으로 NCS 귀� 순이익은 90� 달러(희석 주당순이� 0.34달러)�, 작년 310� 달러 손실(-1.21달러)에서 흑자� 전환되었습니�.

상반� 매출은 18% 증가� 8,650� 달러, 순이익은 500� 달러(희석 주당순이� 1.84달러)� 전환되었습니�. 2분기 매출� 49%� 캐나�, 37%� 미국, 14%� 기타 시장에서 발생했습니다.

재무�. 현금은 2,540� 달러� 건전하며, NCS� 3,500� 달러 ABL 시설� � 푼도 사용하지 않았습니�. � 부채는 770� 달러� 금융리스� 포함합니�. 자본은 1� 2,400� 달러� 증가했습니다.

현금 흐름. 상반� 영업 현금 유입은 운전자본 수요 증가� 410� 달러에서 190� 달러� 감소했으�, 자본적지출은 70� 달러� 적당했습니다.

전략 업데이트. 2025� 7� 31�, NCS� 추적 진단 분야 확장� 위해 Reservoir Metrics� 590� 달러 현금으로 인수했으�, 최대 130� 달러� 추가 지� 조건(언아�)� 있습니다.

위험 � 전망. 경영진은 캐나� 활동은 안정적이�, 미국 완성 작업은 다소 둔화되고, 국제 성장 가능성 � 철강/화학 관세로 인한 비용 압박� 언급했습니다. 캐나� 특허 항소 � 미국 소송� 향후 실적� 영향� 미칠 � 있으�, 현재까지 손익은 반영되지 않았습니�.

Le rapport 10-Q du deuxième trimestre 2025 de NCSM montre un net retournement annuel. Le chiffre d'affaires a augmenté de 23 % pour atteindre 36,5 millions de dollars, porté par une hausse de 46 % des ventes de produits qui a compensé une baisse de 19 % des revenus de services. Le bénéfice brut consolidé s'est amélioré de 2,5 millions de dollars et la perte d'exploitation s'est réduite à 2,0 millions de dollars contre 4,2 millions précédemment. Un avantage fiscal différé de 1,0 million de dollars ainsi que des gains de change ont porté le résultat net attribuable à NCS à 0,9 million de dollars (BPA dilué de 0,34 $) contre une perte de 3,1 millions (-1,21 $) l'année dernière.

Sur six mois, le chiffre d'affaires a progressé de 18 % pour atteindre 86,5 millions de dollars et le résultat net est passé à 5,0 millions de dollars (BPA dilué de 1,84 $). Le Canada a contribué à 49 % des ventes du deuxième trimestre, les États-Unis à 37 % et les autres marchés à 14 %.

Bilan. La trésorerie est restée solide à 25,4 millions de dollars ; NCS n'a tiré aucun montant sur sa facilité ABL de 35 millions. La dette totale se compose uniquement de 7,7 millions en contrats de location-financement. Les capitaux propres ont augmenté à 124,0 millions.

Flux de trésorerie. Les flux de trésorerie d'exploitation du premier semestre ont chuté à 1,9 million contre 4,1 millions en raison d'un besoin accru en fonds de roulement ; les dépenses d'investissement ont été modestes à 0,7 million.

Mise à jour stratégique. Le 31 juillet 2025, NCS a finalisé l'acquisition en numéraire de Reservoir Metrics pour 5,9 millions, afin d'élargir le diagnostic des traceurs, avec un complément de prix pouvant atteindre 1,3 million.

Risques et perspectives. La direction évoque une activité stable au Canada, un ralentissement des opérations de complétion aux États-Unis, une croissance internationale potentielle et des pressions sur les coûts dues aux droits sur l'acier et les produits chimiques. Les appels en matière de brevets au Canada et les litiges aux États-Unis pourraient affecter les résultats futurs, mais aucun gain ou perte n'a été comptabilisé à ce jour.

Der 10-Q-Bericht von NCSM für das zweite Quartal 2025 zeigt eine klare positive Jahresvergleichsentwicklung. Der Umsatz stieg um 23 % auf 36,5 Mio. USD, angetrieben durch einen 46%igen Anstieg der Produktverkäufe, der einen 19%igen Rückgang der Serviceerlöse ausglich. Der konsolidierte Bruttogewinn verbesserte sich um 2,5 Mio. USD, und der operative Verlust verringerte sich von 4,2 Mio. USD auf 2,0 Mio. USD. Ein latenter Steuergewinn von 1,0 Mio. USD sowie Wechselkursgewinne führten dazu, dass der auf NCS entfallende Nettogewinn 0,9 Mio. USD betrug (verwässertes EPS von 0,34 USD) gegenüber einem Verlust von 3,1 Mio. USD (-1,21 USD) im Vorjahr.

Für die ersten sechs Monate stiegen die Umsätze um 18 % auf 86,5 Mio. USD, und der Nettogewinn drehte auf 5,0 Mio. USD (verwässertes EPS von 1,84 USD). Kanada trug 49 % zum Umsatz im zweiten Quartal bei, die USA 37 % und andere Märkte 14 %.

Bilanz. Die Zahlungsmittel blieben mit 25,4 Mio. USD gesund; NCS zog keine Beträge aus seiner 35 Mio. USD ABL-Kreditlinie ab. Die Gesamtschulden bestehen ausschließlich aus 7,7 Mio. USD Finanzierungsleasing. Das Eigenkapital stieg auf 124,0 Mio. USD.

Cashflow. Der operative Cashflow im ersten Halbjahr sank auf 1,9 Mio. USD von 4,1 Mio. USD aufgrund höherer Working-Capital-Bedürfnisse; die Investitionen in Sachanlagen waren mit 0,7 Mio. USD moderat.

Strategisches Update. Am 31. Juli 2025 schloss NCS die Barübernahme von Reservoir Metrics für 5,9 Mio. USD ab, um die Tracer-Diagnostik zu erweitern, mit einem Earn-out von bis zu 1,3 Mio. USD.

Risiken & Ausblick. Das Management nennt stabile Aktivitäten in Kanada, eine schwächere Fertigstellungstätigkeit in den USA, potenzielles internationales Wachstum und Kostendruck durch Stahl-/Chemiezölle. Laufende Patentberufungen in Kanada und Rechtsstreitigkeiten in den USA könnten zukünftige Ergebnisse beeinflussen, es wurden jedoch bisher keine Gewinne oder Verluste verbucht.

false 0001723128 0001723128 2025-08-01 2025-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 1, 2025

 

AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   001-38485   93-4225266
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (908) 947-3120

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.01 per share   AMRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

  

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On August 1, 2025, Amneal Pharmaceuticals, Inc.’s (the “Corporation”) subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Issuer”) borrowed $2.1 billion of new seven-year term B loans (the “New Term Loan”) pursuant to an amendment to the Company’s existing term loan credit facility and completed the previously announced offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Notes”). The Issuer also entered into the ABL Amendment (as defined herein). The Issuer used the net proceeds of the New Term Loan and the Notes to refinance its existing term B loans in full, to repay outstanding amounts borrowed under its ABL facility in full and to pay related fees, premiums and expenses.

 

Amended Term Loan Credit Agreement

 

As previously disclosed, on November 14, 2023, the Company entered into a Term Loan Credit Agreement (the “Existing Term Loan Credit Agreement”) by and among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto (the “Existing Term Loan Lenders”) pursuant to which the Existing Term Loan Lenders extended a term loan (the “Existing Term Loan”) to the Company. The aggregate principal amount of the Existing Term Loan outstanding on August 1, 2025 was approximately $2.26 billion.

 

On August 1, 2025, the Company, entered into an amendment to the Existing Term Loan Credit Agreement (the “Term Loan Amendment”; the Existing Term Loan Credit Agreement, as amended by the Term Loan Amendment, the “Amended Term Loan Credit Agreement”). Pursuant to the Term Loan Amendment, the Company obtained the New Term Loan in the aggregate initial principal amount of $2.1 billion.

 

The New Term Loan is borrowed by the Company and is guaranteed by certain wholly-owned subsidiaries of the Company that guaranteed the Existing Term Loans (together with the Company, the “Loan Parties”).

 

The New Term Loan has a maturity date of August 1, 2032 and amortizes in equal quarterly installments in an amount equal to 1.00% per annum of the original principal amount thereof, with the remaining balance due at final maturity. Interest is payable on the New Term Loans at a rate equal to the term SOFR benchmark rate or the base rate, plus an applicable margin, in each case, subject to a term SOFR benchmark rate floor of 0.50% or a base rate floor of 1.00%, as applicable. The applicable margin for the New Term Loans is 3.50% per annum for term SOFR benchmark rate loans and 2.50% per annum for base rate loans.

 

In addition to extending the maturity date and reducing the applicable margin, in each case, with respect to the Company’s term debt, the Term Loan Amendment modifies the Existing Term Loan Credit Agreement, primarily to provide additional flexibility to the Company and its restricted subsidiaries, including without limitation, with respect to representations and warranties, affirmative and negative covenants and incremental and equivalent term loan facilities.

 

The Loan Parties’ obligations under the Amended Term Loan Credit Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and (ii) all of the equity interests of the subsidiaries of the Loan Parties held by the Loan Parties (except for certain excluded subsidiaries and excluded assets and limited, in the case of the voting equity interests of certain foreign subsidiaries and certain domestic subsidiaries that hold no assets other than equity interests of foreign subsidiaries, to 65% of the voting equity interests of such subsidiaries). The liens securing the New Term Loans will be (x) pari passu in priority with the security interest securing the indebtedness under the Indenture (as defined herein), (y) senior in priority to the security interest securing indebtedness under the Amended Revolving Credit Agreement (as defined herein) to the extent of the Fixed Asset Collateral (as defined in the Indenture) and (z) junior in priority to the security interest securing indebtedness under the Amended Revolving Credit Agreement to the extent of the ABL Priority Collateral (as defined in the Indenture).

 

The foregoing description of the Term Loan Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the complete text of the Term Loan Amendment, a copy of which is being filed as Exhibit 10.1 hereto and is incorporated herein by reference.

 

 

 

Secured Notes Offering

 

The Notes were issued at an issue price of 100.000% of their principal amount pursuant to an Indenture, dated as of August 1, 2025 (the “Indenture”), by and among the Issuer, the guarantors (the “Guarantors”) party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent. The Notes mature on August 1, 2032 and bear interest at a rate of 6.875% per year. Interest on the Notes is payable on February 1 and August 1 of each year, beginning on February 1, 2026.

 

The Issuer may redeem the Notes, in whole or in part, at any time prior to August 1, 2028 at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus an applicable “make whole” premium described in the Indenture. Thereafter, the Issuer may redeem the Notes in whole or in part, at the redemption prices set forth in the Indenture. In addition, at any time on or prior to August 1, 2028, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net cash proceeds of certain equity offerings at a redemption price of 106.875% of the principal amount plus accrued and unpaid interest, if any, to, but not including, the applicable redemption date provided that at least 50% of aggregate principal amount of the Notes remains outstanding. The Issuer may also redeem up to 10% of the aggregate principal amount of the Notes during any 12-month period prior to August 1, 2028 at a redemption price of 103.0% of the principal amount of the Notes being redeemed plus accrued and unpaid interest, if any, to, but not including, the applicable redemption date. If certain changes of control of the Corporation or the Issuer occur, holders of the Notes will have the right to require the issuer to offer to repurchase their Notes at 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.

 

The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis by each of the Issuer’s subsidiaries that guarantees indebtedness under the Amended Term Loan Credit Agreement. The guarantees are subject to release under specified circumstances, including certain circumstances in which such guarantees may be automatically released without the consent of the holders of the Notes.

 

The Notes and the related guarantees are the Issuer’s and the Guarantors’ senior secured obligations and rank equal in right of payment with all existing and future senior indebtedness of the Issuer and the Guarantors and senior in right of payment to all future subordinated indebtedness of the Issuer and the Guarantors. The liens securing the Notes and the guarantees will be (x) pari passu in priority with the security interest securing the New Term Loans, (y) senior in priority to the security interest securing indebtedness under the Amended Revolving Credit Agreement to the extent of the Collateral (as defined in the Indenture, other than the ABL Priority Collateral) and (z) junior in priority to the security interest securing indebtedness under the Amended Revolving Credit Agreement to the extent of the ABL Priority Collateral. In addition, the Notes and the guarantees will be (x) effectively senior to the Issuer’s and the Guarantors’ respective existing and future indebtedness that is unsecured or that is secured by junior liens, in each case to the extent of the value of the Collateral, (y) structurally subordinated to all existing and future indebtedness and other liabilities of any non-guarantor subsidiaries and (z) effectively junior to any of the Issuer’s or any Guarantor’s debt that is secured by assets that are not Collateral, to the extent of the value of such assets.

 

The Notes and the related guarantees will be secured on a first-priority basis by liens on the Fixed Asset Collateral, which consists of substantially all of the assets (other than ABL Priority Collateral) that secure the Issuer’s and the Guarantors’ obligations under the New Term Loans on a pari passu basis, and on a second-priority basis by liens on the ABL Priority Collateral, which generally includes the Issuer’s and the Guarantors’ cash, inventory and accounts receivable and related assets.

 

The Indenture contains customary high yield covenants limiting the ability of the Issuer to: incur additional debt; pay dividends and make other restricted payments; incur liens on assets; enter into certain transactions with affiliates; merge or consolidate or sell all or substantially all of its assets; sell certain assets, including capital stock of subsidiaries; and allow to exist certain restrictions on the ability of restricted subsidiaries to pay dividends or make other payments to the Issuer. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The Indenture also contains customary events of default.

 

The foregoing summary of the Indenture is not complete and is qualified in its entirety by reference to the full text of the Indenture, a copy of which is attached as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

 

 

ABL Amendment

 

As previously disclosed, the Company is a party to a Revolving Credit Agreement, dated June 2, 2022, and as amended on November 14, 2023 (the “Existing Revolving Credit Agreement”) by and among the Company, each of the guarantors party thereto, Truist Bank, as administrative agent, and the other lenders party thereto (the “ABL Lenders”).

 

On August 1, 2025, the Company entered into an amendment to the Existing Revolving Credit Agreement (the “ABL Amendment”; the Existing Revolving Credit Agreement, as amended by the ABL Amendment, the “Amended Revolving Credit Agreement”). The ABL Amendment extends the maturity of the Existing Revolving Credit Agreement to August 1, 2030 and contains modifications to certain provisions of the Existing Revolving Credit Agreement including, without limitation, the representations and warranties and affirmative and negative covenants under the Existing Revolving Credit Agreement, to incorporate most of the modifications that were made to the corresponding provisions in the Amended Term Loan Credit Agreement. The aggregate revolving commitments of the ABL Lenders under the Amended Revolving Credit Agreement continue to be $600,000,000.

 

Interest is payable on loans thereunder at a rate equal to the term SOFR benchmark rate or the base rate, plus an applicable margin, in each case, subject to a term SOFR benchmark rate floor of 0.00% or a base rate floor of 1.00%, as applicable. The applicable margin for such loans is between 1.25% per annum and 1.50% per annum for term SOFR benchmark rate loans and 0.25% per annum and 0.50% per annum for base rate loans, in each case based on historical utilization.

 

The foregoing description of the ABL Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the complete text of the ABL Amendment, a copy of which is being filed as Exhibit 10.2 hereto and is incorporated herein by reference.

 

 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are furnished herewith:

 

Exhibit
No.
 

Description

4.1   Indenture, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent.
10.1   Amendment No. 1 to Term Loan Credit Agreement and Amendment No. 1 to Collateral Agreement, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the lenders party thereto, JPMorgan Chase Bank, NA., as administrative agent and collateral agent, and the bookrunners and arrangers party thereto.
10.2   Amendment No. 2 to Revolving Credit Agreement and Amendment No. 2 to Collateral Agreement, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the other loan parties party hereto, the lenders party hereto and Truist Bank, as administrative agent and collateral agent.
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 1, 2025 AMNEAL PHARMACEUTICALS, INC.
   
  By: /s/ Anastasios Konidaris
  Name: Anastasios Konidaris
  Title: Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

 

 

FAQ

What were NCSM’s Q2 2025 revenues and how did they compare YoY?

$36.5 million, up 23% versus Q2 2024.

Did NCSM report a profit in Q2 2025?

Yes, net income attributable to NCS was $0.9 million or $0.34 diluted EPS, versus a $3.1 million loss last year.

How much cash and debt does NCSM have?

$25.4 million in cash and $7.7 million of finance-lease debt; no borrowings on the $35 million ABL facility.

What is the status of the Reservoir Metrics acquisition?

Closed on 31 July 2025 for $5.9 million cash plus up to $1.3 million earn-out, enhancing tracer diagnostics.

What legal matters could impact future results?

Patent appeals with Kobold in Canada and ongoing U.S. cases with Nine and TCO remain unresolved; no damages or gains are reflected yet.

Which geography contributed the largest share of Q2 2025 revenue?

Canada at 49%, followed by the United States at 37%.
Amneal Pharmaceuticals Inc

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Latest SEC Filings

AMRX Stock Data

2.45B
154.81M
46.75%
43.79%
1.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
Bridgewater